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Abstract 
Background: Atypical Teratoid / Rhabdoid Tumors (ATRT) are known to exhibit molecular and clinical 
heterogeneity even though SMARCB1 inactivation is the sole recurrent genetic event present in 
nearly all cases. Indeed, recent studies demonstrated three molecular subgroups of ATRTs that are 
genetically, epigenetically and clinically distinct. As these studies included different numbers of 
tumors, various subgrouping techniques and naming, an international working group sought to align 
previous findings and to reach a consensus on nomenclature and clinic-pathologic significance of 
ATRT subgroups. 
Methods: We integrated various methods to perform a meta-analysis on published and unpublished 
DNA methylation and gene expression datasets of ATRTs and associated clinico-pathological data.   
Results: In concordance with previous studies, the analyses identified three main molecular 
subgroups of ATRTs, for which a consensus was reached to name them ATRT-TYR, ATRT-SHH, and 
ATRT-MYC. The ATRT-SHH subgroup exhibited further heterogeneity segregating further into two 
subtypes associated with a predominant supratentorial (ATRT-SHH-1) or infratentorial location 
(ATRT-SHH-2). For each ATRT subgroup we provide an overview on its main molecular and clinical 
characteristics, including SMARCB1 alterations and pathway activation. 
Conclusions: The introduction of a common classification, characterization and nomenclature of 
ATRT subgroups will facilitate future research and serve as a common ground for subgrouping 
patient samples and ATRT models, which will aid in refining subgroup-based therapies for ATRT 
patients.  
 
Keywords:  
ATRT, molecular subgroups, meta-analysis, consensus 
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Importance of the study 
The international consensus on number and naming of ATRT molecular subgroups and their main 
characteristics, which we present here, will be important for the design of future clinical trials, 
patient stratification and a uniform classification of patient’s tumor samples, much in line as it has 
been for medulloblastoma, ependymoma and high grade glioma. It will also be essential for a better 
interpretation of preclinical experiments using properly classified in vitro and in vivo ATRT models. 
 
Introduction 
Atypical Teratoid / Rhabdoid Tumors (ATRT) arise in all compartments of the central nervous system 
(CNS), predominantly affect infants or young children, and display a remarkably simple cancer 
genome. Bi-allelic mutation, including partial or whole loss of chromosome 22, resulting in 
inactivation of SMARCB1 are the main - and often only - recurrent molecular features seen in ATRT1. 
Rare cases (<5%) with an intact SMARCB1 harbor mutations in SMARCA4, both encoding 
components of the SWI/SNF chromatin remodeling complex2,3. The recurrent loss of SMARCB1 in 
these tumors is in stark contrast to a pleomorphic histology and considerable molecular and clinical 
heterogeneity observed in ATRT cohorts. Therapeutic strategies in ATRT are largely influenced by the 
age of the patient, tumor location in the CNS and disease stage at diagnosis4. These factors inform 
extent of surgical resection and various radiological and chemotherapeutic interventions. However, 
there is currently no international consensus on standard therapeutic approaches with the majority 
of therapeutic and survival data being published on a center-by-center basis. Numbers of patients 
with ATRT are small, therefore concerted international efforts to evaluate and standardize therapy 
are ongoing.  However, it is as yet unclear how tumor biology shapes the response to treatment, 
outcome and/or long-term effects in patients with ATRT. A critical step towards improving the poor 
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outlook for these patients is therefore to define and characterize the biological heterogeneity in 
ATRT such that a standard subgrouping scheme is available and can be further used to investigate 
subgroup specific features of ATRT and inform subgroup specific therapies. 
Earlier attempts to subgroup ATRT at the transcriptomic level had already recognized a 
degree of heterogeneity, but were limited by a small cohort size5. More recently, international 
efforts to collect and profile significantly larger cohorts of ATRTs have resulted in the identification 
of distinct ATRT subgroups defined by gene expression and/or DNA methylation profiling and 
associated with different molecular and clinico-pathological features (Table 1)6-8. Since the number 
of subgroups and platforms used to identify these subgroups differed between studies, there is an 
urgent need to align findings and define the number, molecular and clinical features and a common 
nomenclature for ATRT subgroups. 
To this end, we performed a meta-analysis of previously published and additional ATRT DNA 
methylation profiles with parallel transcriptomic and clinico-pathological data in order to generate a 
consensus definition and naming for ATRT subgroups and to define their main molecular and clinico-
pathological characteristics.  
 
Materials and Methods 
Integrated analyses of ATRT profiling data 
Due to the variety of datatypes and platforms used previously to subgroup ATRT, we first created a 
composite data set of all cases (n = 388), profiled using the Illumina Infinium HumanMethylation 
450K or EPIC arrays. We excluded all samples (n = 5), which were either duplicates or relapse cases. 
To exclude cases with a low tumor content or outliers for which a high-confidence classification of 
ATRT could not be achieved, we removed all samples (n = 58) with a calibrated score < 0.9 using the 
Heidelberg brain tumor classifier published in Capper et al.9 (www.molecularneuropathology.org). 
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This filtering step aimed to identify potential outlier samples, and generated a high-quality reference 
dataset for classification of subgroups. A number of factors could contribute to a sample failing to be 
classified as ATRT with high-confidence including high non-neoplastic cell content and low quality 
tumor material from archival samples. 
Of remaining 325 samples, 137 had been published in Johann et al.8, 2016, 96 in Torchia et 
al., 20167, and 92 are newly added unpublished samples from the Northern Institute of Cancer 
Research (Newcastle University) (GEO accession no. GSE141363) and the EURHAB study (GEO 
accession no. GSE141039) (Supplementary Table 1). Informed consent was obtained for all cases. In 
order to determine consensus subgroups, methylation array data were subjected to three different 
clustering methods, including consensus non-negative matrix factorization (NMF) (Schwalbe et al., 
201710), regular NMF (Torchia et al., 2015 & Torchia et al., 20166,7) and unsupervised consensus 
clustering (Johann et al., 20168) (Supplementary Methods for full technical details). Algorithms 
chosen had either been previously applied to discover ATRT subgroups or used in consensus 
subgrouping studies for other CNS tumors (i.e. Medulloblastoma11). 
Consensus calls were established by comparison of calls from the three different methods, 
and consensus subgrouping was based on at least equivalent calls from two of the three methods. A 
“no consensus call” was assigned in four cases. As an additional validation step, we corroborated 
consensus calls using t-distributed stochastic neighbor embedding (t-SNE) analysis of the consensus 
dataset. 
To corroborate DNA methylation based classification, we also reanalyzed published 
Affymetrix HG-U133 Plus2.0 expression profiles (n = 97)8,12 and Illumina HT12 v4 gene expression 
array data (n = 60)6 (Supplementary Methods for further information).  
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Results 
 
DNA methylation and gene expression profiling identify three main subgroups of ATRT 
Robust DNA methylation data from 325 unique ATRT cases (Fig. 1) were classified using three 
independent clustering algorithms (consensus NMF, regular NMF, ConsensusClusterPlus) to define 
consensus subgroups of ATRTs. Each method was applied considering a number of possible 
subgroups between two and eight. Clustering metrics (including but not limited to cophenetic 
coefficients, change in area under the cumulative distribution function (CDF) curve, dispersion, 
Kappa, Silhouette score, Supplementary Fig.1) indicated that the most consistently robust clustering 
solution was three subgroups with possible further subclusters identified, as previously discussed in 
Johann et al.8, but supported less robustly here (Fig. 2, Supplementary Fig. 1). There was very high 
concordance between subgrouping based on consensus clustering (97%, 316 cases correctly 
classified), NMF (98%, 318 cases correctly classified), and consensus NMF (99%, 321 cases correctly 
classified), as shown in the Sankey plot in Fig. 2C. Notably, adding back samples excluded for low 
classification calls did not alter number of subgroups as indicated in the t-SNE analysis and cluster 
metrics for the methylation array analyses (Supplementary Fig. 2).  
Given that each clustering method consistently identified three main subgroups of ATRTs, 
with a high degree (>90%) of concordance between the different methods applied (Fig. 2), we chose 
this as the basis of our consensus subgrouping. As shown in Fig. 2A-B, Group 1 annotated cases from 
the Torchia et al. study7  formed one group with the ATRT-SHH cases from the Johann et al. study8, 
while Group 2A and Group 2B annotated cases form groups with either ATRT-TYR or ATRT-MYC 
cases, respectively, indicating that our previous studies identified largely the same three subgroups. 
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We have designated the three subgroups as ATRT-SHH, ATRT-TYR and ATRT-MYC, based on the 
nomenclature proposed by Johann et al.8. 
We next analyzed ATRT gene expression profiles available for a total of 172 cases, profiled 
on Affymetrix HG-U133 Plus2.0 arrays (112, including 15 new cases) or Illumina HT-12 v4 arrays (60 
cases)6. For 21 Affymetrix cases and for 48 Illumina profiled tumors there was matching DNA 
methylation data. Unsupervised hierarchical clustering analysis of the Affymetrix data using 
expression of the 1500 most variable genes confirmed the presence of three major molecular 
subgroups of ATRTs in line with DNA methylation analyses (Fig. 3A). These results remained stable 
across different numbers of differentially expressed genes (data not shown). Subgroup annotations 
were also highly concordant with prior publications where subsets of these data have been 
analyzed8,12; annotated hIC1 cases largely overlapped with the ATRT-SHH cases (8/10), while hIC2 
and hIC3 annotated cases largely overlapped with ATRT-TYR cases (10/12) or ATRT-MYC cases (5/5), 
respectively (Fig. 3A). For the 21 cases with matched Affymetrix gene expression and DNA 
methylation data there was also good concordance with only two samples annotated to different 
subgroups. We assigned final annotation of these two cases based on the DNA methylation data.  
Similarly, unsupervised hierarchical clustering of the Illumina gene expression data also revealed 
three molecular subgroups of ATRTs with a good concordance (96%) between DNA methylation 
array and Illumina based subgrouping (Supplementary Fig. 3). It is worth noting that the clustering 
metrics derived from the Affymetrix data also supported three main and not additional subgroups 
(Supplementary Fig. 4B). 
Finally, in order to gain further insights into the biology of the subgroups, we performed 
ingenuity pathway and gene set enrichment analyses for which the normalized enrichment scores 
are shown in Fig. 3B as a radar plot. Overall, the ATRT-SHH subgroup displayed a low overlap of 
enriched gene sets with ATRT-TYR and ATRT-MYC, but there was some overlap between ATRT-TYR 
and ATRT-MYC – in particular for gene sets related to immune response. The specific gene 
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enrichment features as well as comments on known published genes for each subgroup separate are 
described below.  
 
Molecular and clinical features of the three subgroups 
Having identified and confirmed the presence of three main molecular subgroups of ATRTs, we 
examined available pooled molecular and clinico-pathological data of all cases to define the main 
characteristics of each group as described below and shown in Fig. 4 (and an overview on 
cytogenetic aberrations in Supplementary Fig. 5).  
 
Correlations of the three subgroups with published ATRT models. 
In the last years, a number of cell lines and genetically engineered mouse models have been 
established to model ATRT tumorigenesis. In order to see how these match our consensus human 
ATRT subgrouping, we collected RNAseq and gene expression data from previously published 
studies12-14 and performed a Multidimensional scaling (MDS) analysis, sample-wise correlation 
between cell lines and mouse models against human ATRT samples (Supplementary Fig. 6A,C), and 
unsupervised hierarchical clustering analysis on the combined human and mouse datasets using 
orthologous genes (Supplementary Fig. 6B). Results of this preclinical model characterization are 
discussed below in the respective sections.  
 
ATRT-TYR 
The ATRT-TYR subgroup was named after the enzyme tyrosinase, which is highly overexpressed in 
most ATRT-TYR cases, but not in the other ATRT subgroups or other brain tumors, indicating it may 
be a good diagnostic marker for ATRT-TYR cases15. The protein physiologically catalyzes the synthesis 
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of melanin in melanocytes and is an important protagonist in neural tube development16. Although 
the role of TYR in ATRT tumorigenesis remains to be established, it is notable that several other 
components of the melanosomal pathway, including the tyrosinase related protein TYRP and the 
melanoma-oncogene MITF, are also upregulated in this subgroup, potentially reflecting restricted 
neuroectodermal origins17. 
Other pathways and genes upregulated in ATRT-TYR tumors include the BMP-pathway (e.g. 
BMP4) and developmentally related transcription factors such as OTX2 (Supplementary Fig. 4A). 
Gene set enrichment analysis performed on the differentially overexpressed genes confirms the 
melanosomal pathway and tyrosine metabolism (Fig. 3B, “GO [developmental] Pigmentation”, “GO 
Pigment granule organization”) as well as epithelial proliferation as being enriched in ATRT-TYR (Fig. 
3B). Although comprehensive histopathological studies of ATRT molecular subtypes remain pending, 
it is notable that cribriform neuroectodermal tumors (CRINET), which also all express TYR, have DNA 
methylation profiles that are highly similar to ATRT-TYR tumors18, suggesting that CRINET and ATRT-
TYR tumors may represent two histological variants with a common cell of origin. Whether the 
favorable outcomes of CRINET patients18 also applies to patients with ATRT-TYR tumors remains to 
be investigated. 
Genetically, the prototypic type of bi-allelic SMARCB1 inactivation in the ATRT-TYR group is 
whole or partial loss of one copy of chromosome 22 accompanied by an inactivating (e.g. point-) 
mutation in SMARCB1 on the other allele (Fig. 4C-D). The loss of chromosome 22 was more 
prevalent in ATRT-TYR (86 versus 59 cases in ATRT-SHH and 16 cases in ATRT-MYC; p = 0.053, chi 
square test). Investigations using ATAC-seq revealed that this subgroup harbors a more open 
chromatin, suggestive of a more primitive epigenetic landscape as compared to the other ATRT 
subgroups7. 
Clinically, ATRT-TYR patients represent the youngest patient group with median age at 
diagnosis of 12 months (range 0 – 108 months). This subgroup also contained the highest proportion 
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of patients under three years at time of diagnosis (90% in ATRT-TYR vs 74.6% in ATRT-SHH vs 52.3% 
in ATRT-MYC (Fig. 4A, Supplemental Table 1). Most (75%, 52 of 69 with location data) ATRT-TYR 
tumors have infratentorial location and only 25% (17 cases) are located supratentorially (Fig. 4B). 
This differs significantly from ATRT-SHH and ATRT-MYC, which are more often localized 
supratentorially (p-value = 2.21e-09, chi square test). A recent radiogenomics study of ATRT 
molecular subgroups suggested that ATRT-TYR tumors may have MRI appearance characterized by a 
band like enhancement of contrast media19. 
For preclinical studies, the number of available in vitro and in vivo models for ATRT remains 
very limited and the number of models with molecular subgroup information is even more limited. 
In a recently published study by Brabetz et al.20, three ATRT patient xenograft models from the SHH 
and MYC subgroups were included but none of the analyzed xenografts exhibited the profile of 
ATRT-TYR. The study of Torchia et al.7 classified eight ATRT cell lines as three representing Group 1 
(equivalent to ATRT-SHH) and five representing Group 2 (equivalent to ATRT-TYR/ATRT-MYC). 
However, so far it remained unclear how many of the Group 2 cell lines represent ATRT-TYR (Group 
2A) tumors and how many of these represent ATRT-MYC (Group 2B). Aiming to answer this question, 
we have analyzed the available transcriptomic data for these cell lines. For CHLA02, CHLA04 and 
CHLA05 the allocation to the ATRT-SHH subgroup is confirmed as expected by unsupervised 
hierarchical clustering and visualized in the MDS plot (Suppl. Fig. 6). For the remaining cell lines 
(BT12, BT16, SH, CHLA266, CHLA06), allocation to either ATRT-TYR or ATRT-MYC has so far not been 
performed. Projection from the MDS plot, correlation analysis and unsupervised clustering 
(Supplementary Fig. 6A-C) indicate that BT12, BT16, CHLA06, CHL266, and SH, can clearly be 
allocated to ATRT-MYC. These five cell lines, previously characterized as Group 2, all exhibited high 
expression of MYC and elevated HOX gene expression in some, but all lacked the TYR group 
signature (see Suppl. Fig. 6D). Taken together, these data suggests these cell lines are likely all 
derived from ATRT-MYC tumors. 
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Additional models have been employed in several other publications investigating drug 
targets in ATRT xenografts, but the subgroup identity of these models remain unknown. In the cell 
line BT37 for instance, the role of HMGA2 as an oncogene has been highlighted21. This protein is 
overexpressed specifically in ATRT-TYR (Supplementary Fig. 4), suggesting that BT37 may represent 
an ATRT-TYR model. While numerous studies have examined drug targets in ATRT irrespective of 
their subgroup, knowledge on subgroup specific vulnerabilities is sparse. PDGFRB for example, has 
been shown to be a drug target in Group 2 cell lines BT12, BT16, CHLA266, CHLA06, and SH, and they 
all displayed a higher susceptibility to PDGFRB inhibitors Nilotinib and Dasatinib than Group 1 (ATRT-
SHH) cell lines. Again, whether this means that both ATRT-TYR and ATRT-MYC tumors can be 
targeted by these inhibitors remains to be seen as PDGFRB expression levels in ATRT-TYR tumors are 
much higher than in ATRT-MYC tumors (Supplementary Fig. 4). Transcriptome analyses further 
suggest other promising drug targets that have or have not been tested already in rhabdoid tumors. 
For instance, FGFR2 is specifically upregulated in ATRT-TYR and FGFR signaling (together with PDGFR 
inhibition) has been described as a vulnerability in rhabdoid tumors22,23. Another possible candidate 
is JAK1, a protein tyrosine kinase overexpressed in ATRT-TYR that regulates the JAK-STAT signaling 
cascade. Approved inhibitors such as Ruxolitinib are available and hold the promise of a possible 
targeted therapy. Further drug screening using robustly subgrouped cell lines will be important to 
determine which of the prior preclinically tested substances have subgroup specificity.  
 
ATRT-SHH  
The ATRT-SHH subgroup, in the Torchia et al. publication also referred to as Group 17, displays an 
overexpression of both SHH and NOTCH pathway members, such as for instance GLI2, PTCH1, and 
BOC (all SHH pathway) or ASCL1, HES1, DTX1 (all regulators of the NOTCH pathway; Supplementary 
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Fig. 4A). Protein expression of ASCL1, a neuronal differentiation transcription factor, has been 
suggested as an immunohistochemical marker for this subgroup6. Moreover, Torchia et al. (2015) 
showed that ASCL1 protein expression could be a biomarker for improved survival suggesting that 
ASCL1-positive ATRT-SHH (Group 1) cases have a better overall survival than ASCL1-negative (Group 
2) ATRTs6. However, as ASCL1 is not expressed in all samples of the SHH subgroup and can also be 
expressed in some cases of the other subgroups, it remains to be seen whether patients with ATRT-
SHH tumors have a better outcome than other ATRT patients. More analyses on prospective cohorts 
of ATRT patients are needed to see whether there are survival differences between the three 
molecular subgroups defined by DNA methylation.  
Beyond the oncogenic signaling pathways, gene set enrichment analyses confirmed previous 
observations that ATRT-SHH is mainly a neuronally differentiated subgroup with enrichment of 
genes involved in “axon guidance pathways” and “neuronal system” pathways, as compared to 
other subgroups (Fig. 3B).  
Torchia et al. showed using siRNA and Gamma secretase inhibitors that the Group 1/SHH cell 
lines dependent on NOTCH signaling for growth7. However, therapeutic significance of SHH signaling 
for ATRT-SHH remains to be tested as unlike SHH-activated medulloblastomas in the MB-SHH 
subgroup, genomic aberrations of SHH pathway members including PTCH1, SMO or SUFU, have to 
date not been found in any ATRT-SHH. All SHH pathway marker genes overexpressed in this 
subgroup (such as e.g. GLI2) are thus most likely directly or indirectly activated by the SMARCB1 loss 
in these tumors as reported previously24. Why SMARCB1 loss does not activate the SHH pathway to 
the same extent in the other subgroups remains unknown but maybe related to different cellular 
origin for these subgroups. Thus, whereas clear therapeutic indication for SHH pathway inhibitors 
has been established for SHH MB, the role of Vismodegib and other SMO inhibitors in ATRTs is 
unclear and remains to be further investigated25. 
D
ow
nloaded from
 https://academ
ic.oup.com
/neuro-oncology/advance-article-abstract/doi/10.1093/neuonc/noz235/5691191 by U
niversity of N
ew
castle user on 07 January 2020
Ac
ce
pte
d M
an
us
cri
pt
N-O-D-19-00610R1 – Molecular subgrouping of Atypical Teratoid/Rhabdoid Tumors (ATRT) 
 
15 
 
Genetically, ATRT-SHH cases differ from the other two subgroups regarding the type of 
SMARCB1 alterations. Most ATRT-SHH cases display compound heterozygous point mutations (p < 
0.00025, chi-square test) as compared to the other groups (Fig. 4C), while homo- or heterozygous 
SMARCB1 deletions are less frequently found in this subgroup compared to the other groups (66 
from 134 samples, 44% in ATRT-SHH vs 77% in ATRT-TYR and 64% in ATRT-MYC) (Fig. 4D). With 
regards to age, ATRT-SHH represent a more intermediate subgroup (median age 20 months, range 0 
– 96), with patients on average younger than ATRT-MYC patients and older than ATRT-TYR patients. 
ATRT-SHH tumors can have either a supratentorial (56/68, 75%) or infratentorial localization 
(30/68, 35%) (Fig. 4B). However, as reported previously8, DNA methylation analyses suggest a 
further molecular heterogeneity within the ATRT-SHH subgroup. Indeed, when performing cluster 
analyses for ATRT-SHH profiles only, we find that the ATRT-SHH subgroup splits up in two subtypes 
associated with either a mainly supratentorial location (ATRT-SHH-1) or mainly infratentorial 
location (ATRT-SHH-2) (Supplementary Fig. 7A-B). The split in two subtypes is supported by 
consensus clustering when analyzing the SHH subgroup separately (data not shown). It is important 
to note that both subtypes of ATRT-SHH express marker genes from the NOTCH and SHH pathways. 
More samples and analyses are needed to investigate whether there are other molecular or clinical 
differences between these two SHH subtypes. From a radiological point of view, MRI analysis of 
ATRT-SHH tumors revealed that this is the only subgroup containing tumors that extend both infra- 
and supratentorially. Moreover, there was a lower degree of contrast enhancement in these tumors 
compared to ATRT-TYR and ATRT-MYC19.  
With respect to in vivo models, the xenograft lines ATRT-310FH and ATRT-311FH have been 
classified as ATRT-SHH and may thus represent a good tool for future studies20. Interestingly, a 
Rosa26CreERT2;Smarcb1flox/flox  mouse model of rhabdoid tumors reported by Han et al. develop 
spontaneous brain tumors, a subset of which have gene expression profiles very similar to that of 
human ATRT-SHH (shown in Supplementary Fig. 6A-C)12. Similarly, a Snf5 Flox/Flox /p53 lox/lox 
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/GFAP-Cre (as derived from the study of Ng et al.13) rhabdoid model seem to be closer to SHH than 
to the other subgroups. In general development of ATRT in murine models seem to require 
inactivation of Smarcb1 during early embryonic (E6-E7) development suggesting very early 
progenitors as cells of origin. Regarding in vitro models the CHLA02, CHLA04, and CHLA05 cell lines, 
all represent ATRT-SHH (formerly Group 1)7. Overexpressed drug targets that merit further 
investigation include the tyrosine kinase DDR1, but also EZH2, which is a candidate drug target for 
ATRT in general26. In vitro studies have shown that cell lines derived from ATRT-SHH (Group 1) 
tumors are more sensitive to EZH2 inhibitors7. Of note, recent epigenomic characterizations of 
primary ATRT suggest EZH2 overexpression in ATRT is not accompanied by global increase of 
repressive mark H3K27me327, indicating additional non-enzymatic functions of EZH2 may be 
important in ATRTs 28. Although promising preclinical data have fueled phase I trials using EZH2 
inhibitors (e.g. with Tazemetostat, NCT02601937), it remains to be seen if this therapeutic regimen 
will be efficacious in the clinical setting. 
 
ATRT-MYC 
The ATRT-MYC subgroup was named based on elevated expression of the MYC oncogene as opposed 
to the MYCN oncogene which is enriched in the ATRT-SHH group. However, different from other 
MYC or MYCN-driven pediatric brain tumors like MB-Group 3, MB-SHH, or HGG-MYCN, MYC or 
MYCN amplifications have not been observed respectively in ATRT-MYC or ATRT-SHH tumors. In 
addition, one of the most striking patterns at the mRNA expression pattern in these tumors is the 
overexpression of several HOXC cluster genes (Fig. 3B), driven by super enhancers8, i.e. very long 
stretched enhancers with abundant H3K27ac signal. Similar to ATRT-TYR, a broad categorization into 
neuronal and mesenchymal subgroups would assign these tumors a more mesenchymal expression 
profile7. The typical genetic pattern that leads to SMARCB1 inactivation in these tumors is a 
homozygous, broad loss of SMARCB1 (which is present in 42/74 cases, 57%), covering several 100 
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kb7,8. In contrast to ATRT-TYR or ATRT-SHH tumors, point mutations are rare in ATRT-MYC tumors 
(Fig. 4C).    
The median age of ATRT-MYC patients is significantly higher than in the two other subgroups 
(27 months, range 0 - 190.9, Fig. 4A). This is mainly due to a number of older patients and not 
primarily due to a lack of very young patients in this subgroup.  
Although a majority of ATRT-MYC tumors arise supratentorially (25/50, 50%), all spinal 
tumors in our cohort (6/50, 12%) were of the ATRT-MYC sub-group (Fig. 4B). MRI studies suggest 
ATRT-MYC tumors are distinguished by presence of a strong peritumoral edema19. Of note, recent 
reports have highlighted similarities between extracranial MRT and ATRT-MYC on the DNA 
methylation level29,30. As the DNA methylation profile of tumor entities i  highly reflective of the cell 
of origin, it raises the question if these entities may share common cellular origins, and whether the 
behavior of ATRT-MYC tumors may more closely resemble extracranial RTs. Of note, recent studies 
of adult ATRT suggest these fall mostly in the ATRT-MYC group and suggest further clinical and 
molecular heterogeneity in ATRT-MYC may be revealed28. 
 We have shown here that several cell lines (BT12, BT16, CHLA266, CHLA06, SH) described by 
Torchia et al.7 (Supplementary Fig. 6C-D) exhibit features more similar to the ATRT-MYC than to the 
ATRT-TYR subgroup. Several xenograft models of these cell lines suitable for in vivo drug testing have 
been reported20,31. Our correlative analysis of GEMM and ATRT primary samples also revealed that 
as subset of the published tumor samples generated from P0-CreC;Smarcb1 flox/flox mice display 
high correlation with ATRT-MYC samples and may thus represent a model for the ATRT-MYC 
subgroup (Suppl. Fig. 6A-B)14.  
Given the previously mentioned similarities between ATRT-MYC and a subgroup of Rhabdoid 
Kidney tumors (RTK), common molecular targets between extracranial rhabdoid tumors and 
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subgroups may exist. In fact, Oberlick et al.32 found indeed a dependency of both eMRT and ATRT 
cell lines on a number of RTKs thus highlighting novel drug targets in these tumors.      
 
Discussion 
Identification of distinct molecular subgroups in an otherwise relatively genetically homogeneous 
disease has been a major step in further understanding the molecular heterogeneity of ATRTs (Fig. 
5)6-8,12. In this study we aimed to establish a consensus regarding the number of ATRT subgroups, 
their main molecular and clinical characteristics and a commonly accepted nomenclature in order to 
enable a better understanding of the clinical heterogeneity in ATRTs. Here, we have shown that the 
three molecular subgroups identified in previous studies based on DNA methylation and/or gene 
expression profiling closely match with each other and a consensus was reached to name them 
ATRT-TYR, ATRT-SHH, and ATRT-MYC, according to the nomenclature published by Johann et al.8 The 
activated genes or pathways, which were chosen for this nomenclature, emerged when performing 
overexpression analyses. However, their biological and therapeutic role in ATRT requires further 
investigation.  
A consensus on number and naming of molecular subgroups has in other entities like 
medulloblastoma33, ependymoma34, or glioblastoma35, proven to be essential for a uniform 
classification of patient’s tumor samples, subgroup specific experiments using properly classified 
preclinical in vitro and in vivo models, and ultimately for the design of clinical trials and patient 
stratification. A further heterogeneity within these main three ATRT subgroups may still exist, similar 
to what has been reported for medulloblastoma or ependymoma subgroups for instance36,37. Thus 
far, DNA methylation profiling has identified two further subtypes within the ATRT-SHH subgroup, 
which correlates with predominant supratentorial (ATRT-SHH-1) or infratentorial locations (ATRT-
D
ow
nloaded from
 https://academ
ic.oup.com
/neuro-oncology/advance-article-abstract/doi/10.1093/neuonc/noz235/5691191 by U
niversity of N
ew
castle user on 07 January 2020
Ac
ce
pte
d M
an
us
cri
pt
N-O-D-19-00610R1 – Molecular subgrouping of Atypical Teratoid/Rhabdoid Tumors (ATRT) 
 
19 
 
SHH-2), but larger cohort studies are needed to better define molecular differences between these 
subtypes and whether they are clinically relevant.  
As the outcome for ATRT patients is still relatively poor, new treatment strategies are 
urgently needed. Identification and characterization of ATRT subgroups may help discovery of 
subgroup specific treatments, but will also help to elucidate new pan-ATRT therapies. Given the 
reported relatedness of ATRT-MYC to extracranial rhabdoids, these investigations should also 
include extracranial malignant rhabdoid tumors (MRT) such as those occurring in the kidney, liver, or 
other soft tissues29,38. Additionally, more molecularly characterized models, including cell lines, 
patient-derived orthotopic xenograft models and tumor organoid cultures, which represent the 
molecular spectrum of ATRTs are needed to critically advance ATRT therapeutics.   
The prognostic value of the ATRT subgroups remains to be fully investigated. Torchia et al. 
reported ASCL1 protein expression, which is highly expressed in ATRT-SHH, was associated with a 
better outcome6. However, it is not clear whether this is true for the whole SHH subgroup as not all 
ATRT-SHH cases may express ASCL1. There clearly is a need for assessing the predictive power of the 
subgroups in well characterized cohorts in prospective, clinical studies. 
Finally, to get a better understanding of the clinical relevance of ATRTs subgroups, molecular 
subgrouping should be included in any future clinical trial for ATRT patients. The method of choice is 
currently DNA methylation profiling as this requires very little input material (tumor DNA isolated 
from either frozen or formalin-fixed paraffin-embedded tumor tissue), and shows little or no bias 
when performed at different centers. However, as DNA methylation profiling may not always be 
available, it would still be helpful if more readily available markers or methods to subgroup ATRTs, 
such as immunohistochemical staining for tyrosinase or ASCL1, or Nanostring subgrouping methods 
as has been developed for medulloblastoma, could also be developed for broader use in clinical labs 
globally.  
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Figure legends: 
 
Figure 1: Overview flow charts on all analyses and samples. 
 
Figure 2: Methylation array analysis of the consensus dataset. 
a) Unsupervised hierarchical Clustering using the top 5000 most variable CG sites confirms the 
presence of three subgroups in the consensus dataset (325 samples). 
b) t-SNE visualization of the analyzed dataset based on the 5000 most variable CG sites reproduces 
segregation into three main ATRT subgroups. Coloring of data points in the t-SNE plots displays the 
subgrouping as published in Johann et al.8 (upper plot) or in Torchia et al.7 (lower plot). Half 
transparent circles show the consensus subgroups used in this paper.  
c) Sankey plot displaying the concordance between the subgroup calls using different methods 
(NMF, Consensus Clustering and NMF+KM based subgrouping). Numbers in each subgroup show the 
number of samples which have been assigned to the subgroup with the respective method.   
 
 
Figure 3: Cluster analysis based on Affymetrix array gene expression data.  
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a) Unsupervised hierarchical clustering using the top 1500 most variable genes in the consensus 
gene expression dataset. Annotations in the lower bar show the grouping as presented in Han et al.12 
and in Johann et al.8 and the current methylation consensus calls.  
b) Visualization of GSEA results as a radar plot. Axis displays the normalized enrichment values. Each 
ATRT subgroup is represented in the respective subgroup color.  
 
Figure 4: Clinical and genetic associations of ATRT subgroups. 
a) Violin plots of age distribution in ATRT subgroups. 
b) Frequency of CNS tumor location by consensus subgroup represented by pie charts. 
c) Oncoprint figure displays the distribution of various types of SMARCB1 mutations among the 
consensus set. 
d) Distribution of SMARCB1 alterations and chr22 changes in the consensus set as determined by 
methylation array analyses, represented by pie charts.  
Significance between subgroups was calculated with chi square test. 
 
Figure 5: Consensus overview on ATRT subgroups. 
Schema of salient clinical and molecular characteristics of ATRT subgroups. 
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Study Subgroups 
Methods/platforms used 
(n = # cases) 
 
Torchia et al., 
2015 
Group 1 
Overexpression 
of ASCL1 
Group 2 
 
Immunohistochemistry 
(ASCL1) (n = 170) 
Gene expression array profiling 
(IIlumina HT12) (n = 43) 
Torchia et al., 
2016 
Group 1 
Overexpression 
of NOTCH 
pathway genes 
ASCL1, CBL, 
HES1 
Group 2A 
Overexpression 
of neuronal 
and 
mesenchymal 
genes  
OTX2, PDGFRB, 
BMP4 
Group 2B 
Overexpression 
of HOX cluster 
genes 
Methylation array profiling 
(Illumina 450K) (n = 162) 
Gene expression array profiling 
(IIlumina HT12) (n = 90) 
Johann et al., 
2016 
ATRT-SHH 
Overexpression 
of SHH 
pathway genes 
GLI2, BOC, 
PTCHD2, MYCN 
 
ATRT-TYR 
Overexpression 
of 
melanosomal 
genes  
TYR, TYRP, 
MITF, OTX2 
ATRT-MYC 
Overexpression 
of MYC and 
HOX cluster 
genes 
Methylation array profiling 
(Illumina 450K) (n = 150) 
Gene expression array profiling 
(Affymetrix U133plus2.0) (n = 69) 
Han et al., 
2016 
hIC2 
Overexpression 
of ASCL1, BOC, 
SOX2, GLI2, 
FABP7 
hIC1 
Overexpression 
of BMP4, 
OTX2, SMAD7 
hIC3 
Overexpression 
of ACTL6A, 
FABP7, GFAP 
 
Gene expression array profiling 
(Affymetrix U133plus2.0) (n = 30) 
 
Table 1: Summary of defining transcriptional features of ATRT subgroups. Data derived from 
publications [8-10]. 
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Figure 1 
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